RxDoctor Payments Data

Bassel Hassouna, MD

Interventional Cardiology · Wayne, MINPI 1780918946

Payments from drug & device makers

$24,810in general payments, 2019–2025

Across 238 payments — averaging $104.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$18K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$911
  • Merck$559
  • Johnson & Johnson$543
  • Boehringer Ingelheim$493
  • AstraZeneca$460
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$6,81927%
  • Education$1991%
  • Other$17,79272%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,810 in reported general payments places this provider in the 65th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$342,023
Medicare patients
650
Services billed
4,371

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban204$224,715
EntrestoSacubitril/Valsartan71$100,598
XareltoRivaroxaban106$94,939
FarxigaDapagliflozin Propanediol26$25,012
MultaqDronedarone Hcl13$20,344
BrilintaTicagrelor25$18,621
VerquvoVericiguat11$11,635
Ranolazine ErRanolazine66$5,483
Metoprolol Succinate226$3,685
Isosorbide Mononitrate ErIsosorbide Mononitrate211$2,950
Atorvastatin Calcium216$2,876
Carvedilol216$2,061
Nadolol25$1,883
ClopidogrelClopidogrel Bisulfate119$1,800
Losartan Potassium119$1,571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$58$224,715204 claims
NovartisEntresto$279$100,59871 claims
Johnson & JohnsonXarelto$543$94,939106 claims
AstraZenecaFarxiga, Brilinta$460$43,63351 claims
Sanofi-aventis U.S. LLCMultaq$86$20,34413 claims
MerckVerquvo$559$11,63511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Wayne

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →